Prognosis of ductal adenocarcinoma of pancreatic head with overexpression of CD44  by Hwang, Tsann-Long et al.
Formosan Journal of Surgery (2014) 47, 138e144Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e-f js .comORIGINAL ARTICLEPrognosis of ductal adenocarcinoma
of pancreatic head with overexpression
of CD44
Tsann-Long Hwang a,*, Li-Yu Lee b, Tse-Ching Chen b,
Ashok Thorat a, Jen-Ter Hsu a, Chun-Nan Yeh a, Ta-Sen Yeh a,
Yi-Yin Jan aa Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, Taiwan
b Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, TaiwanReceived 27 May 2014; received in revised form 28 July 2014; accepted 17 August 2014
Available online 8 October 2014KEYWORDS
cancer stem cells;
immunohistochemical
staining;
CD44;
pancreatic ductal
adenocarcinoma;
surface markersConflict of interest: The authors h
* Corresponding author. Departmen
Taiwan.
E-mail address: hwangtl@adm.cgm
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1682-606X/Copyright ª 2014, TaiwanSummary Background: The long-term survival rate of patients with pancreatic ductal adeno-
carcinoma (PDAC) is very low. Cancer stem cells have been identified in PDAC based on the
expression of the surface markers CD24, CD44, CD133, and epithelial specific antigen. The
prognosis of PDAC may be related to the presence or absence of tumor cells with cancer stem
cell surface markers.
Methods: Eighty-six PDAC patients (51 male and 35 female patients) who underwent surgical
treatment at Chang Gung Memorial HospitaldLin-Kou Medical Center, Lin-Kou, Taiwan be-
tween 1998 and 2007 were included in this study. The patients’ ages ranged from 30 years
to 84 years. All their surgical specimens showed invasive ductal cancer. Immunohistochemical
staining with CD44 antibodies was performed. The differences in clinical data, cell types of tu-
mors, tumor staging, and survival rates between patients with CD44 (Group A; n Z 33) and
CD44þ (Group B; n Z 53) were compared.
Results: Clinical data, cell types of tumors, and tumor staging between the two groups showed
no significant differences. The 3- and 5-year survival rates were, respectively, 51.5% and 19.8%
in patients with CD44 tumor cells and 4.0% and 2.0% in those with CD44þ tumor cells. The dif-
ferences were statistically significant (p < 0.0001). The median overall survival times of the
two groups were also different (36.9 months vs. 12.2 months, p < 0.0001). Multivariate analysis
showed that the CD44 as well as lymph node status, and differentiation of tumor cells were
prognostic factors for patients with PDAC.ave no conflicts of interest to declare.
t of Surgery, Chang Gung Memorial Hospital, Number 5, Fu-Hsin Street, Kwei-Shan, Tao-Yuan 330,
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Prognosis of CD44 overexpression in pancreatic cancer 139Conclusion: The results suggested that CD44 expression in patients with PDAC after surgery
was significantly associated with decreased survival, whereas patients with CD44 tumor cells
survived significantly longer.
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reserved.1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the
leading causes of cancer deaths in the Western world, and
is the 10th most common cancer in Taiwan. Complete sur-
gical resection still remains the only therapeutic option for
PDAC, but only 10% of patients are candidates for curative
surgery.1 The overall 5-year survival rate is 5e10%, which is
much lower than that of resectable pancreatic cancer in
general (25e35%).2e4
Malignant tumors usually comprise a heterogeneous cell
population having different biologic properties, of which a
small population of cancer cells, or so-called cancer stem
cells (CSCs), promote tumor formation and growth.5 The
existence of CSCs was first proved in acute myelogenous
leukemia6,7 and subsequently verified in breast8 and brain
tumors.9e11 Al-Hajj et al8 reported a phenotypically distinct
and relatively rare population having CD44þ, CD24, and
epithelial-specific antigenþ, and stated that the tumor-
initiating cell lineage was responsible for the propagation
of human metastatic breast cancer cells. Pancreatic CSCs
have not been identified until Li et al12 described a sub-
population of tumor cells from PDAC tissue with increased
tumorigenic potential in mice. They also identified putative
CSCs in PDAC based on the expression of the surface
markers CD44, CD24, and epithelial specific antigen.
The expression of CD44 variants has been reported to
correlate with a poor prognosis in colon cancer.13 Over-
expression of CD44 has also been demonstrated to be
associated with poor prognoses in head and neck squamous-
cell carcinoma.14,15 In human pancreatic cancer samples,
CD44 expression was reported to correlate with the histo-
logic grade, and patients with CD44-positive tumors showed
a poor prognosis.16 The present study was designed to
compare the prognosis of PDAC patients with positive or
negative expression of CD44 in tumor cells after surgical
resection.
2. Materials and methods
2.1. Patients and specimens
A total of 751 patients were diagnosed to have PDAC at the
Department of Surgery in Chang Gung Memorial Hospital at
Lin-Kou, Taiwan between 1998 and 2007, and only 370 of
them (49.3%) underwent surgical resection. Tumor speci-
mens from 86 patients with resection of the pancreatic
head, who were alive after the operation during the study
period, were retrieved for this study. Our pathologists have
reviewed the slides to ensure that the tissues were
consistent with PDAC. The study was approved by the EthicsCommittee of our hospital and performed according to the
Helsinki Declaration.
2.2. Grouping
The patients were divided into two groups. Those patients
whose pancreatic CSC showed CD44 (N Z 33) were clas-
sified as Group A, and those with CD44þ (N Z 53) were
classified as Group B. Clinical data, and differentiation and
staging of tumors using pancreatic cancer staging of AJCC
(American Joint Committee on Cancer) seventh edition,17
obtained from the pathological reports of patients, were
compared between the two groups. The survival of patients
between these groups was also compared.
2.3. Immunohistochemistry
Immunohistochemical staining18 was performed on 3e4 mm
sections of formalin-fixed, paraffin-embedded tissues,
placed on coated glass slides and dried at 60e70C for 30
minutes. CD44 was detected by the monoclonal body HCAM
(DF1485; Santa Biotechnology Inc., Dallas, TX, USA). Using
the antibody detection method, two polymer-based sys-
tems and one streptavidinebiotin system were tested. For
double-labeling with cytokeratin 19 or chromogranin A,
standard methods employed in routine diagnostic service
were used after adjusting antibody concentrations. Antigen
retrieval was performed by incubation in a pressurized
heating chamber at 120C for 1 minute in Tris-EDTA buffer
(pH 9). The slides were then cooled by placing them under
running tap water and incubated with primary antibody
diluted 1:25 in an antibody diluent with reduced salt con-
centration (25 mM Tris, 75 mM NaCl, 1% BSA (bovine serum
albumin), 0.01% methiolate, and 0.05% Tween 20; pH 7.4)
for 60 minutes. Next, unspecific peroxidase activity was
blocked by 3% H2O2 treatment for 5 minutes. Primary
antibody detection was performed, in accordance with the
manufacturer’s instructions, using the MACH3 mouse probe
for 20 minutes, followed by MACH3 HRP (horseradish
peroxidase) polymer for 20 minutes, and the signal was
developed with diaminobenzidine DAB þ for 5 minutes.
Between every two steps, there were two washing steps for
1 minute each on a rocking platform in washing buffer
(50 mM Tris, 150 mM NaCl, and 0.05% Tween 20; pH 7.5).
Finally, the slides were counterstained with hematoxylin
for 1 minute, dehydrated in alcohol solutions and xylene,
and mounted in Entellan.
2.4. Assessment of immunohistochemical staining
The quality of staining was judged in the control material
from different organs, on the basis of the data available in
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various tissue types. TMA (tissue microarray) slides con-
taining PDAC were scored independently by two of the
authors (L.Y.L. and T.C.C.) as negative (0), weakly positive
(1), or strongly positive (2) for CD44 expression. Cases with
different scores were discussed to reach an agreement. As
validation for TMA interpretation, whole sections from the
border between the adenocarcinoma and nearby non-
tumorous pancreatic tissue were made from 10 of the cases
included in the TMA blocks, and treated and evaluated in
the same way as the TMA slides. Parallels were stained
with hematoxylin and eosin for controlling the tissue
quality. The whole sections were also screened at
1000  magnification, looking for features such as nuclear/
cytoplasmic staining, expression in vessels, etc.
2.5. Statistical analysis
Statistical analyses were performed using the SPSS (SPSS
Inc., Chicago, IL, USA). The product-limit (KaplaneMeier)
analysis module was used for comparing survival rates be-
tween multiple groups. Multivariate analysis of prognostic
factors was performed using the Cox proportional hazard
method. Survival times versus cumulative proportion sur-
viving, according to breakdown by the staining intensity for
Group A and Group B, were plotted.
3. Results
3.1. Patients’ clinical data
Patients’ clinical data and tumor staging between the two
groups are listed in Table 1. Differences in age, levels of
albumin, GOT, ALK-P, and hemoglobin between the two
groups were not significant. Tumor markers, such as CEA
and CA19-9, also showed no significant differences between
these groups.Table 1 Clinical data of patients in the two groups.
Group A
(n Z 33)
CD 44 ()
Group B
(n Z 53)
CD 44 (þ)
p
Age (y) 61.6  10.1 61.6  9.4 0.988
Albumin (g/dL) 3.8  0.6 3.8  0.6 0.934
GOT (U/L) 156.6  118.9 56.4  222.9 0.997
ALK-P (U/L) 387  422 356  280 0.698
Hb (g/dL) 12.1  1.8 12.2  1.7 0.805
CEA (ng/mL) 9.1  12.9 5.0  5.5 0.136
CA19-9 (ng/mL) 1121  2740 1021  3617 0.906
Differentiation 0.352
Well 12 (46.2) 14 (53.8)
Moderate 13 (34.7) 32 (65.3)
Poor 4 (50.0) 4 (50.0)
Undifferentiated 0 3 (100.0)
Stage 0.421
I 4 (57.1) 3 (42.9)
II 29 (36.7) 50 (63.3)
Data are presented as n (%) or mean  SD.
Hb Z hemoglobin.3.2. Expression in PDAC
CD44 expression was evaluated in a series blocks. Fifty-
three cases (61.6%) were positive, and expression was
mainly seen in the apical/endoluminal cell surface in ma-
lignant ductal structures (Fig. 1). In the positive cases, the
expression area and intensity varied with the morphological
heterogeneity of the tumor. Thirty-three cases (38.4%)
were negative for CD44 expression.
3.3. Prognosis in the two groups
The median overall survival time of patients in the CD44
group were 36.9 months, whereas that in the CD44þ group
was only 12.2 months, and the difference between the two
groups was significant (p < 0.0001). The 3- and 5-year
survival rates of patients were, respectively, 51.5% and
19.8% in the CD44 group and only 4.0% and 2.0% in the
CD44þ group, and the differences between the two groups
were also significant (p < 0.0001). The cumulative survival
curve is shown in Fig. 2A.
For more detailed analysis, we compared between the
patients with stage IIA and IIB cancers. The median overall
survival time of patients with stage IIA cancer in the CD44
group (n Z 13) was 36.9 months, whereas that (n Z 10) in
the CD44þ group was only 15.7 months, and the difference
between the two groups was significant (pZ 0.042). The 3-
and 5-year survival rates of patients, were, respectively,
53.8% and 34.6% in the CD44e group, whereas 10% and 0% in
the CD44þ group, and the differences between these
groups were also significant. The cumulative survival curve
is shown in Fig. 2B.
For patients with Stage IIB cancer, the median overall
survival time was 17.8 months in the CD44 group (nZ 16)
and only 10.9 months in the CD44þ group (n Z 40), and
the difference between these groups was significant
(p Z 0.001). The 3- and 5-year survival rates of patients
were, respectively, 50.0% and 18.8% in Group A, whereas
those were 0% in Group B, and the difference between the
two groups was also significant. The cumulative survival
curve is shown in Fig. 2C.
Results of the univariate and multivariate analyses of
the relative risk factors between the two groups of patients
are presented in Tables 2 and 3; only lymph node status,
differentiation, and CD44 were significant.
4. Discussion
The prognosis of PDAC is extremely poor, because the
cancer usually invades the surrounding tissues and metas-
tasizes to lymph nodes, liver, or peritoneum at the time of
diagnosis. CD44 is an adhesion molecule and membrane
receptor for hyaluronan, and is involved in cell motility and
metastasis. The gene encoding CD44 generates a variety of
isoforms by alternative splicing, which predominantly af-
fects the extracellular membrane-proximal structure of
CD44 proteins.19 Prince et al20 demonstrated that CD44
cells isolated from primary head and neck carcinoma have
the ability to self-renew and differentiate in an in vivo
mouse model, and the CD44 subpopulation in primary tu-
mors vary from 0.1% to 42%. In other tumors, multiple cell
Figure 1 CD44 expressions in pancreatic ductal adenocarcinoma tumor tissues. (A and B) CD44-positive expression (brown) in
exocrine tissue is most abundant in centroacinar regions and intercalated ducts in two patients. (A0 and B0) Higher magnification of
the areas marked in A and B, respectively. (C and D) CD44 negative staining in two other patients. (C0 and D0) Higher magnification
of the areas marked in C and D, respectively. Scale bar: (AeD) 50 mm and (A0eD0) 125 mm.
Prognosis of CD44 overexpression in pancreatic cancer 141surface markers may be used to purify CSCs, and CD44 has
been used as one of the CSC markers.
CD44 is a member of the transmembrane glycoprotein
family, with a large number of isoforms identified in many
human tissues and particularly high expression in prolifer-
ating cells and squamous cell epithelium. The CD44 variant
6 (v6) molecule has been noted as a marker for tumormetastasis and prognosis in several tumors. Although
Gansauge et al21 reported that lower serum levels of solu-
ble CD44 v6 were significantly associated with poor prog-
nosis in patients with PDAC, this might not be the true
reflection of prognosis of CD44þ in patients with PDAC.
Gotoda et al22 first reported that CD44 v2 and CD44 v6 may
be useful markers of a poor prognosis.
Figure 2 KaplaneMeier 1-, 3-, and 5-year overall survival curves for (A) all pancreatic ductal adenocarcinoma patients (nZ 86),
(B) patients with stage IIA cancer, and (C) patients with stage IIB cancer. The higher curve represents the patients with negative
CD44-expressing tumor, and the lower curve represents those with a strong CD44 expression. The differences in three curves
between CD44 and CD44þ groups were significant (p < 0.05). OS Z overall survival.
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Table 2 Univariate analysis of relative factors between the two groups.
Parameters N Median
(mo)
95% CI p
Sex Male 50 12.16 8.60e25.73 0.272
Female 36 17.23 14.90e19.56
Age (y) 50 10 17.39 0.00e49.74 0.478
>50 76 14.06 9.47e18.55
Jaundice Yes 72 16.11 12.13e20.09 0.293
No 14 13.97 9.48e18.47
OP type Whipple 58 18.08 12.00e20.15 0.554
PPPD 28 12.69 4.62e20.76
CA19-9 (U/L) 37 16 32.42 3.03e61.80 0.003
>37 70 12.99 8.74e17.23
T status T1 4 8.45 NA 0.731
T2 35 12.69 8.42e16.96
T3 47 16.11 14.27e17.95
Nodal status Negative 30 17.39 13.80e20.79 0.025
Positive 56 11.87 6.79e16.55
Stage I 7 58.46 29.91e87.00 0.262
II 79 14.01 9.77e18.24
Margin Negative 62 16.04 13.76e18.33 0.056
Positive 24 11.87 6.32e17.02
Differentiation Well 26 27.03 19.92e34.13 0.003
Moderate 49 10.36 7.60e13.11
Poor 8 12.69 7.27e18.11
Others 3 5.06 2.96e7.17
Vascular invasion No 62 15.75 12.02e19.49 0.187
Yes 24 12.99 6.09e19.88
Lymphatic invasion No 44 16.04 13.75e18.34 0.104
Yes 42 11.67 9.03e14.31
Perineural invasion No 20 14.01 6.87e21.14 0.633
CD44 Yes 66 15.85 11.28e20.42 <0.0001
Negative 33 36.92 11.34e62.51
Positive 53 12.16 8.94e15.39
Chemotherapy No 31 10.32 1.19e19.46 0.528
Yes 55 16.08 10.89e21.26
CI Z confidence interval; NA Z not available; PPPD Z pylorus-preservation pancreaticoduodenectomy.
Prognosis of CD44 overexpression in pancreatic cancer 143In this study, we demonstrated that the overexpression
of CD44 had a statistically significant association with
decreased 5-year overall survival in patients with PDAC
after surgery. The prognosis of patients with CD44 was
better with significantly improved survival, but the tumor
staging between the two groups of patients showed no such
difference. The main factor seems to be related to the
presence or absence of tumor stem cells in their PDAC.Table 3 Multivariate analysis of relative factors between the t
Parameters
CA19-9 >37/37
Lymph node status N1/N0
Margin Positive/negative
Differentiation Moderate/well
Poor/well
Undifferentiated/well
CD44 Positive/negative
CI Z confidence interval; HR Z hazard ratio.It has been shown that, in several cancers, only a mi-
nority of the cancer cells are able to initiate the formation
of new tumors. These cancer-initiation cells are called
CSCs, and in several studies the CD44 adhesion molecule
has been demonstrated to be expressed specifically in these
cells. It has been shown that CD44þ cancer cells contain
cancer stem-cell like properties and can initiate in vivo
tumor formation. Moreover, in recent studies, CSCs havewo groups (using Cox proportional hazard method).
Hazard ratio 95% CI of HR p
1.649 0.871e3.124 0.125
1.772 1.059e2.965 0.029
1.289 0.771e2.153 0.332
1.974 1.149e3.390 0.014
2.954 1.250e6.981 0.014
5.915 1.253e27.918 0.025
2.190 1.271e3.972 0.005
144 T.-L. Hwang et al.also been shown to have increased resistance to drug and
radiation therapies.23,24 In the present study, we showed
that CD44 overexpression is associated with poor prognosis,
which may suggest that cancer cells strongly expressing
CD44 have qualities linked to the CSCs. These results sup-
port the hypothesis that increased cell adhesion supports
the growth of cancer cells, both in primary tumors and in
metastases.
CD44þ cells reconstitute the resistant cell population,
and CD44 could be a therapeutic target to overcome the
drug resistance during gemcitabine chemotherapy for
pancreatic cancer. Hence, CD44 targeted therapy is a
possible option for reversing chemoresistance of pancreatic
cancer cells.16 Veapamil has been shown to be an inhibitor
of ABC transporters,25 and treatment with verapamil can
resensitize resistance cells to gemcitabine therapy.
In conclusion, CD44 overexpressions in patientswith PDAC
after surgery are significantly associated with decreased
survival, whereas patients with CD44 tumor cells survive for
a significantly longer time. Cancer stem-like cells play a
pivotal role in acquiring multidrug resistance in pancreatic
cancer, and in particular, CD44 cells, which repopulate after
chemotherapy, were responsible for chemoresistance. In
therapeutic application, targeted therapy against CD44
could be applied to overcome drug resistance and might be
beneficial in the treatment of pancreatic cancer.Acknowledgments
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